In today’s wrapup of Triangle tech and life science news:

  • Chimerix says antiviral didn’t improve survival rates
  • Cary-based Chiesi USA buys cardiovascular products
  • Durham-based Measurement, Inc. loses a big contract

The details:

Durham-based drug company Chimerix reported Monday that its antiviral candidate did not improve the survival rates of infected patients.

“Chimerix said the antiviral, called brincidofovir, rapidly reduced the levels of adenovirus in infected patients, even to the point that that the deadly virus could not be detected in the body,” reports John Murawski of The News and Observer. However, there was no “meaningful difference” in survival rates.

See details at:

  • Chiesi USA’s product acquisition

Cary-based Chiesi USA has acquired some cardiovascular product rights from The Medicines Company.

“The three products acquired are for use in the hospital setting and approved for sale in the United States. Financial details were not disclosed,” according to Jason deBruyn of The Triangle Business Journal.

See details at:

  • Tennessee yanks $108M Measurement, Inc. contract

Durham-based Measurement, Inc. has lost a $108 million testing contract with the state of Tennessee, reports Alex Dixon of the Durham Herald-Sun.

“[B]ut Measurement Inc.’s CEO says Tennessee never gave his company a chance to resolve problems, Dixon wrote.

See details at: